Keywords: novartis, zometa, eu, ok, cancer-related, bone, complications

Novartis' Zometa EU OK for cancer-related bone complications

Article | 29 July 2002

Novartis' Zometa (zoledronic acid) has been granted marketingauthorization by the European Medicines Evaluation Agency for the prevention of skeletal-related multiple ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing

Related Drugs

zoledronic acid

Zometa

Go to drug listing